A Milestone for Shorla Oncology


Orlaith Ryan, Chief Technical Officer and Co-Founder of Shorla Oncology said: “The FDA’s action today ensures that Shorla is well positioned to bring this innovative oral drug to market. SH-201 addresses key areas of unmet need by providing a palatable liquid treatment option for patients suffering with cancer.”

Read more at: Women Mean Business